Abel Joseph
Masters Student in Epidemiology and Clinical Research, admitted Autumn 2024
All Publications
-
Clinical outcomes of D-POEM for epiphrenic diverticula: An international multicenter experience of full-thickness septotomy versus submucosal tunneling
INTERNATIONAL JOURNAL OF GASTROINTESTINAL INTERVENTION
2026; 15 (1): 37-42
View details for DOI 10.18528/ijgii250098
View details for Web of Science ID 001695073600006
-
Outcomes of Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Neoplasms: A Multicenter North American Experience.
Gastrointestinal endoscopy
2025
Abstract
Endoscopic submucosal dissection (ESD) is recommended as the standard of care for treating superficial esophageal squamous neoplasms (ESN). However, the data in the Western world is limited. This study aims to describe the outcomes of ESD for ESN in North America.We conducted a multi-center retrospective analysis of patients who underwent ESD for superficial ESN at 13 North American academic centers. The primary outcomes were the rates of en bloc, R0, and curative resection. Patient demographics, technical outcomes, clinical outcomes, and adverse events were also reported.A total of 150 patients (39% female, mean age 70±10 years) underwent ESD to treat superficial ESN with an average tumor size of 36.6±27.0 mm. En-bloc resection rates for all, LGD/HGD, M1/M2, and M3/SM1 lesions were 97%, 97%, 100%, and 94%, respectively. R0 resection rates for all, LGD/HGD, M1/M2, and M3/SM1 lesions were 73%, 84%, 89%, and 70%, respectively. Curative resection rates for all, LGD/HGD, M1/M2, and M3/SM1 lesions were 55%, 84%, 86%, and 61%, respectively. Adverse events were observed in 25 patients (16.6%). The median follow-up time was 15.7 months (IQR 6.1-28.0). Local recurrence occurred in 12 (8.0%) cases, 3 (2%) cases from curative resection and 9 (6%) cases in non-curative resection (p = 0.04). Metastasis occurred in 8 (5.3%) of all included cases and was only evident in non-curative resections. During this period, 21 (14.0%) patients died of non-ESCC-related causes, and 7 (4.7%) patients died from ESCC.ESD is a safe and effective treatment for superficial ESN with a low recurrence rate in lesions that meet the standard criteria for curative resection.
View details for DOI 10.1016/j.gie.2025.12.270
View details for PubMedID 41456748
-
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023
LANCET
2025; 406 (10513): 1873-1922
Abstract
For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions.The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution.Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant).Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors-eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic-the complex interaction of multiple health risks, social determinants, and systemic challenges-will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity.Gates Foundation and Bloomberg Philanthropies.
View details for DOI 10.1016/S0140-6736(25)01637-X
View details for Web of Science ID 001606031100001
View details for PubMedID 41092926
View details for PubMedCentralID PMC12535840
-
The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
LANCET
2025; 406 (10512): 1565-1586
Abstract
Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050.Cancer estimation in GBD 2023 used data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Cancer mortality was estimated using ensemble models, with incidence informed by mortality estimates and mortality-to-incidence ratios (MIRs). Prevalence estimates were generated from modelled survival estimates, then multiplied by disability weights to estimate years lived with disability (YLDs). Years of life lost (YLLs) were estimated by multiplying age-specific cancer deaths by the GBD standard life expectancy at the age of death. Disability-adjusted life-years (DALYs) were calculated as the sum of YLLs and YLDs. We used the GBD 2023 comparative risk assessment framework to estimate cancer burden attributable to 44 behavioural, environmental and occupational, and metabolic risk factors. To forecast cancer burden from 2024 to 2050, we used the GBD 2023 forecasting framework, which included forecasts of relevant risk factor exposures and used Socio-demographic Index as a covariate for forecasting the proportion of each cancer not affected by these risk factors. Progress towards the UN Sustainable Development Goal (SDG) target 3.4 aim to reduce non-communicable disease mortality by a third between 2015 and 2030 was estimated for cancer.In 2023, excluding non-melanoma skin cancers, there were 18·5 million (95% uncertainty interval 16·4 to 20·7) incident cases of cancer and 10·4 million (9·65 to 10·9) deaths, contributing to 271 million (255 to 285) DALYs globally. Of these, 57·9% (56·1 to 59·8) of incident cases and 65·8% (64·3 to 67·6) of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group classifications. Cancer was the second leading cause of deaths globally in 2023 after cardiovascular diseases. There were 4·33 million (3·85 to 4·78) risk-attributable cancer deaths globally in 2023, comprising 41·7% (37·8 to 45·4) of all cancer deaths. Risk-attributable cancer deaths increased by 72·3% (57·1 to 86·8) from 1990 to 2023, whereas overall global cancer deaths increased by 74·3% (62·2 to 86·2) over the same period. The reference forecasts (the most likely future) estimate that in 2050 there will be 30·5 million (22·9 to 38·9) cases and 18·6 million (15·6 to 21·5) deaths from cancer globally, 60·7% (41·9 to 80·6) and 74·5% (50·1 to 104·2) increases from 2024, respectively. These forecasted increases in deaths are greater in low-income and middle-income countries (90·6% [61·0 to 127·0]) compared with high-income countries (42·8% [28·3 to 58·6]). Most of these increases are likely due to demographic changes, as age-standardised death rates are forecast to change by -5·6% (-12·8 to 4·6) between 2024 and 2050 globally. Between 2015 and 2030, the probability of dying due to cancer between the ages of 30 years and 70 years was forecasted to have a relative decrease of 6·5% (3·2 to 10·3).Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050 and a disproportionate growth in burden in countries with scarce resources. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for 2030. Effectively and sustainably addressing cancer burden globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer-control strategies across the continuum of prevention, diagnosis, and treatment.Gates Foundation, St Jude Children's Research Hospital, and St Baldrick's Foundation.
View details for DOI 10.1016/S0140-6736(25)01635-6
View details for Web of Science ID 001601147600001
View details for PubMedID 41015051
View details for PubMedCentralID PMC12687902
-
Outcomes of Submucosal Tunneling Endoscopic Resection for Subepithelial Tumors in the Upper Gastrointestinal Tract: Experience from the United States.
Gastrointestinal endoscopy
2025
Abstract
Data on outcomes of submucosal tunneling endoscopic resection (STER) for upper gastrointestinal (UGI) subepithelial lesions (SELs) in Western countries is limited. This study assesses the outcomes of STER for UGI SELs in US centers.This retrospective analysis included UGI SELs referred for STER at eight US centers. Study included lesions originating or inseparable from the muscularis propria (MP) layer, SELs with symptoms, potential malignancy on endoscopic ultrasound (EUS), or inconclusive EUS-fine needle aspiration (EUS-FNA) but suspected gastrointestinal stromal tumor (GIST).A total of 47 patients with 51 SELs (median size 25 mm) were included; 42 (82.3%) had prior sampling. Median procedure time was 89.8 minutes. Submucosal fibrosis (SF) was present in 19.6% lesions, all with prior sampling history. En bloc resection and retrieval were achieved in 94.1% lesions. Transmural resection (TMR) was needed in 21.6% of the lesions and was significantly associated with extraluminal extension (OR 8.4), GIST histology (OR 6.0), and SF (OR 5.8). TMR was linked to a higher rate of R1 resection (OR: 4.1) and longer procedural time (>90 minutes, OR 8.6), without an increased risk of adverse events (AEs). AEs occurred in 7/47 (14.8%) patients and were managed conservatively. No lesion recurred within a median follow-up of 17 months.STER is a safe and effective approach for selected UGI SELs. Extraluminal extension, GIST histology, and SF predict the need for TMR. R1 resection was more common with TMR with increased procedural time. Minimizing pre-resection sampling may reduce fibrosis and optimize outcomes.
View details for DOI 10.1016/j.gie.2025.09.011
View details for PubMedID 40962234
-
Outcome of colonoscopic decompression in acute colonic pseudo-obstruction: A systematic review and meta-analysis.
World journal of critical care medicine
2025; 14 (3): 102733
Abstract
Acute colonic pseudo-obstruction (ACPO) is defined as colonic obstruction without a mechanical or extrinsic inflammatory factor. Colonic decompression is advised for patients with ACPO after the failure of conservative and medical management.To systematically review and analyze the efficacy and safety of colonoscopic decompression in ACPO.A search was conducted in MEDLINE, EMBASE, and Scopus from inception to August 2024. Studies reporting the clinical success, perforation, recurrence, and need for surgery after colonoscopic decompression in ACPO were included. A random-effects inverse-variance model was used to calculate the pooled proportion.Sixteen studies were included in the final analysis. The pooled rates of success after the first session of colonoscopic decompression and overall success were 78.8% (95%CI: 72.0-85.6) and 91.5% (95%CI: 87.0-96.0), respectively. The first session of colonoscopic decompression had a significantly higher success than the first dose of neostigmine with OR 3.85 (95%CI: 2.00-7.42). The pooled incidence of perforation was 0.9% (95%CI: 0.0-2.0), while recurrence was observed in 17.1% (95%CI: 12.9-21.3) of the patients after clinical success. The pooled rates of surgery in all cases undergoing colonoscopic decompression and those who had a successful procedure were 10.5% (95%CI: 5.0-15.9) and 3.7% (95%CI: 0.3-7.1), respectively. Subgroup analysis, excluding the low-quality studies, did not significantly change the event rates.Colonoscopic decompression for ACPO is associated with a clinical success rate of > 90% with a perforation rate of < 1%, demonstrating high efficacy and safety.
View details for DOI 10.5492/wjccm.v14.i3.102733
View details for PubMedID 40880578
View details for PubMedCentralID PMC12304928
-
Endoscopic submucosal dissection for drainage of esophageal abscess with fish bone extraction.
VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy
2025; 10 (9): 460-463
Abstract
Foreign body ingestion with submucosal penetration presents a challenging clinical scenario. We present a case of successful endoscopic submucosal dissection (ESD) for removing an embedded fish bone with drainage of an associated submucosal abscess.A 49-year-old woman presented with odynophagia after fish bone ingestion. Computed tomography scan identified a linear density in the upper esophagus. After an initial negative esophagogastroduodenoscopy, a repeat procedure revealed a submucosal abscess. The ESD technique was used to drain the abscess and retrieve the fish bone.The fish bone was successfully removed using ESD technique without immediate or delayed adverse events. Postprocedure management included antibiotics, proton pump inhibitor therapy, and dietary modification. Follow-up esophagram confirmed absence of fistula or abscess.This case demonstrates the importance of careful endoscopic assessment and the utility of ESD technique in managing superficial esophageal abscesses. ESD is a safe and effective technique for removing embedded esophageal foreign bodies within the submucosa.
View details for DOI 10.1016/j.vgie.2025.04.005
View details for PubMedID 40843088
View details for PubMedCentralID PMC12366426
-
Traction methods in endoscopic submucosal dissection: a narrative review
ANNALS OF LAPAROSCOPIC AND ENDOSCOPIC SURGERY
2025; 10
View details for DOI 10.21037/ales-25-4
View details for Web of Science ID 001545896200007
-
Clinical Outcomes of Endoscopic Submucosal Dissection for Residual Neoplasia After Incomplete Resection of Large Non-Pedunculated Colorectal Polyps: A Large Multicenter Propensity Match Study.
Gastrointestinal endoscopy
2025
Abstract
Data on endoscopic submucosal dissection (ESD) for residual neoplasia after incomplete resection (ER) of large non-pedunculated colorectal polyps (LNPCPs) remains scarce. We aimed to evaluate and compare outcomes of ESD in treatment naïve (control) lesions vs. those with prior failed ER.Multicenter propensity-score (PS) match study of ESDs performed for LNPCPs between January 2021 to September 2024. The following covariates were used for PS calculation: age, sex, and lesion characteristics (size, location, morphology, histology). Endpoints included: rates of en-bloc and R0 resection, adverse events and neoplasia recurrence on surveillance.A total of 1447 consecutive patients underwent ESD during the study period. PS match resulted in the selection of 361 (control) and 184 (prior failed ER) strictly matched 2:1 pairs. En-bloc and R0 resection rates were similar between the control and prior failed ER arms: 91.7% vs 89.7%; p=.44 and 80.9% vs. 81.0%; p=.98, respectively. There was no difference in the rate of perforation between the control and prior failed ER arms (4.7% vs. 4.4%; p=1.00), whereas there was non-statistically significant trend towards higher delayed bleeding in the prior failed ER group (1.63% vs. 0.83%, relative risk: 1.96; p=0.40). Neoplasia recurrence on surveillance was 3.6% in the control and 5.8% in the prior failed ER group (p=0.32).ESD can be performed safely and effectively as a salvage therapy after failed attempt at ER of LNPCPs. ESD may be selectively considered as part of our endoscopic armamentarium for the management of these difficult-to-treat lesions. support current guideline endorsed indications for ESD for the treatment of residual neoplasia after incomplete ER.
View details for DOI 10.1016/j.gie.2025.07.026
View details for PubMedID 40706906
-
Journey to complete remission of dysplasia and intestinal metaplasia after ESD and EMR of Barrett's esophagus-related neoplasia.
Endoscopy international open
2025; 13: a24222815
Abstract
Although endoscopic submucosal dissection (ESD) is associated with higher en-bloc and R0 resection rates than cap-assisted endoscopic mucosal resection (cEMR), its comparative impact on achieving complete remission of dysplasia (CRD) and intestinal metaplasia (CRIM) in BE endoscopic eradication therapy (EET) is not well defined. We aimed to compare the journey of patients from initial endoscopic resection (ER) with ESD and cEMR to achieving CRD and CRIM.Patients undergoing ESD or cEMR followed by ablation for BE neoplasia at two academic institutions in the United States were included. Primary outcomes included CRD and CRIM rates following ER in the two groups. Secondary outcomes included the number of resection/ablative procedures from initial ER to achieving CRD and CRIM. Inverse probability treatment weighting (IPTW) was used to balance confounding variables between groups.A total of 801 patients (606 cEMR, 195 ESD) were included. ESD group patients had higher en-bloc resection rates (ESD 94.4%, cEMR 44.7%). Higher rates of CRD were observed in patients undergoing initial ESD (HR 1.53, P < 0.01). With time-to-event and IPTW analyses, rates of achieving CRD and CRIM were comparable between the groups. There were no significant differences in mean number of endoscopic resection or ablative procedures among patients undergoing initial cEMR resection compared with those treated with initial ESD.Despite larger lesion sizes and more cancers in patients undergoing ESD, the EET journey to achieving CRD and CRIM was comparable to that in patients receiving cEMR. Prospective studies are required to further study differences between these two treatment approaches.
View details for DOI 10.1055/a-2422-2815
View details for PubMedID 40376017
View details for PubMedCentralID PMC12080518
-
Endoscopic Submucosal Dissection for Previously Attempted Colorectal Lesions: An International Multicenter Experience.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025
Abstract
Salvage endoscopic submucosal dissection (ESD) has been proposed for previously attempted colorectal lesions (PACLs), yet the extensive submucosal fibrosis impacts procedural difficulty and resection outcomes. The aim of this study is to evaluate the efficacy and safety of salvage ESD for the treatment of PACLs.This international, multicenter study enrolled consecutive patients who underwent ESD to manage PACLs. Rates of en bloc, R0 resection, and local recurrence were assessed for efficacy. Safety was assessed by adverse events (AEs), procedure-related mortality, and the need for surgical management.Of 415 lesions, en bloc rate was 83.4%, R0 76.2%, and curative resection 73.5%. AEs occurred in 48 (11.8%) patients, the most common being intraprocedural perforation (n=19; 4.6%). Two patients required surgical management and 17 were managed endoscopically. Significant intraprocedural bleeding occurred in 3 (0.7%), all managed endoscopically. 25 patients (6.0%) had post-ESD AEs at the median of 5 (IQR 1-24) days, most commonly being delayed bleeding (2.4%). Of 260 patients with follow-up data (median 49 (25-72) weeks), local recurrence occurred in 18 (6.9%). Surgical referral was made in 25 patients (6.0%) due to noncurative resection (5%), intraprocedural perforation (0.4%), and post-ESD AEs (0.4%, colonic stricture and fistula formation). There was no mortality from procedure-related or colorectal cancer.Salvage ESD is highly effective in the treatment of PACLs. When performed by experts, AEs were uncommon and mostly managed endoscopically.
View details for DOI 10.1016/j.cgh.2025.02.021
View details for PubMedID 40349895
-
Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019
NATURE COMMUNICATIONS
2025; 16 (1): 4235
Abstract
Chronic care manages long-term, progressive conditions, while acute care addresses short-term conditions. Chronic conditions increasingly strain health systems, which are often unprepared for these demands. This study examines the burden of conditions requiring acute versus chronic care, including sequelae. Conditions and sequelae from the Global Burden of Diseases Study 2019 were classified into acute or chronic care categories. Data were analysed by age, sex, and socio-demographic index, presenting total numbers and contributions to burden metrics such as Disability-Adjusted Life Years (DALYs), Years Lived with Disability (YLD), and Years of Life Lost (YLL). Approximately 68% of DALYs were attributed to chronic care, while 27% were due to acute care. Chronic care needs increased with age, representing 86% of YLDs and 71% of YLLs, and accounting for 93% of YLDs from sequelae. These findings highlight that chronic care needs far exceed acute care needs globally, necessitating health systems to adapt accordingly.
View details for DOI 10.1038/s41467-025-56910-x
View details for Web of Science ID 001489978400001
View details for PubMedID 40335470
View details for PubMedCentralID PMC12059133
-
Pyloric Dysfunction: A Review of the Mechanisms, Diagnosis, and Treatment.
Gut and liver
2025
Abstract
Pyloric dysfunction is defined as hypertonia or spasm of the pyloric sphincter. The pylorus plays a key role in gastric emptying, but its function remains incompletely understood. Most studies have focused on gastroparesis regardless of the underlying pathophysiology. Few studies have reported pyloric dysfunction in patients with gastroparesis, and the diagnostic and treatment modalities for pyloric dysfunction are not well established. Recently developed diagnostic modalities assessing pyloric function, such as high-resolution antroduodenal manometry and endoluminal functional lumen imaging, are currently being evaluated. A variety of therapeutic interventions targeting the pylorus, including pharmacologic agents, intrapyloric botulinum injection, endoscopic balloon dilation, stent insertion, surgical pyloroplasty, and gastric peroral endoscopic pyloromyotomy, have been proposed. Among these, gastric peroral endoscopic pyloromyotomy has emerged as a novel, minimally invasive therapy with demonstrated efficacy and safety for refractory gastroparesis. This article reviews the pathophysiology of pyloric dysfunction and the potential diagnostic and therapeutic modalities based on the latest literature.
View details for DOI 10.5009/gnl240421
View details for PubMedID 40058793
-
Novel Modified Endoscopic Suction Overtube for Clearance of Gastric Blood Clots During Urgent Upper Endoscopy
LIPPINCOTT WILLIAMS & WILKINS. 2024: S2153
View details for DOI 10.14309/01.ajg.0001042120.39605.12
View details for Web of Science ID 001359318700041
-
Esophageal Distensibility Changes as Measured by EndoFLIP in Different Esophageal Motility Disorders
LIPPINCOTT WILLIAMS & WILKINS. 2024: S405-S406
View details for DOI 10.14309/01.ajg.0001031716.26674.cc
View details for Web of Science ID 001360324500041
-
Timing of Index Ileocolic Resection is Associated With Radiographic Recurrence in Patients With Crohn's Disease
LIPPINCOTT WILLIAMS & WILKINS. 2024: S962-S963
View details for DOI 10.14309/01.ajg.0001034752.01061.8f
View details for Web of Science ID 001365068500038
-
Efficacy and safety of covered self-expandable metal stent for malignant hilar biliary obstruction: A systematic review and meta-analysis.
Gastrointestinal endoscopy
2024
Abstract
Covered self-expanding metal stents (C-SEMS) are used for malignant hilar biliary obstruction (MHBO) management. Despite increasing evidence, comprehensive evaluation of the efficacy and safety of C-SEMS in MHBO management is lacking.PubMed, EMBASE, and the Cochrane Library were screened up to March 31, 2024 for studies including MHBO treated by a C-SEMS. Studies meeting predefined inclusion criteria, including adult MHBO patients treated with C-SEMS placement, reporting technical success, clinical success, and adverse event rates, were selected. Data synthesis and statistical analysis were performed using the random effects model, with heterogeneity and publication bias assessment.From 401 articles, seven studies were included. Pooled technical and clinical success rate of C-SEMS was 96.7% (95% CI 92.6-98.6%, I2=0%) and 91.6% (95% CI 86.1-95.0%, I2=0%). Overall adverse events were reported in 16.6% (95% CI 11.2-23.9%, I2=24%) of cases which included cholangitis (7.4%), pancreatitis (5.9%), liver abscess (5.9%), and cholecystitis (2.8%). Stent migration and recurrent biliary obstruction were observed in 8.9% and 49.6% of cases, respectively, with a median time to recurrent biliary obstruction of 142 days. Reintervention was successful in 92.5% of cases (95% CI 83.1-96.9%, I2=0%) CONCLUSION: Our meta-analysis revealed high technical and clinical success rates of C-SEMS in MHBO. Adverse events, notably cholangitis, cholecystitis, and pancreatitis were <10%. RBO and stent migration was mitigated by C-SEMS removal and successful reintervention. Our findings highlight the efficacy and safety of C-SEMS in managing MHBO, warranting further research to optimize treatment strategies.
View details for DOI 10.1016/j.gie.2024.09.037
View details for PubMedID 39357660
-
Esophageal Expert Development of a Preliminary Question Prompt List for Adults With Eosinophilic Esophagitis: A Modified Delphi Study.
Journal of clinical gastroenterology
2024
Abstract
Question prompt lists (QPLs) are structured sets of disease-specific questions intended to encourage question-asking by patients and enhance patient-physician communication. To date, an EoE-specific QPL has not been developed for EoE patients.To develop a preliminary QPL specific to adults with EoE by incorporating input from international esophageal experts.Sixteen experts were invited to generate QPL content through a modified Delphi (RAND/University of California, Los Angeles, CA) method consisting of 2 rounds of independent ratings. In round 1, experts provided 5 answers to the prompts "what general questions should patients ask when being seen for EoE?" and "what questions do I not hear patients asking but given my experience, I believe they should be asking?" In round 2, experts rated each question on a 5-point Likert scale, and responses rated as "essential" or "important" (determined by an a priori median threshold of ≥ 4.0) were accepted for the EoE QPL.Ten esophageal experts participated in both rounds. Round 1 generated 100 questions. Questions were combined and modified to reduce redundancy, yielding 57 questions. After round 2, 51 questions (85%) were accepted for inclusion (median value ≥ 4.0) in the final QPL. Questions were then divided into 4 themes based on disease domains: (1) "What is EoE?," (2) "Treatment Options," (3) "Follow-up Surveillance and Long-term Risks," and (4) "Allergy and Genetic Testing." The largest number of questions covered was "What is EoE?" (16/51 or 31%). Questions with the highest agreement median (5.0) included examples such as "what should I do if I get a food impaction?" and "what are the treatment options?"This is the first preliminary EoE QPL developed in the field of medicine. We hope implementation enhances effective patient-physician communication by encouraging patients to ask relevant questions that experts prioritized. Future studies will aim to modify this communication tool by incorporating patient perspectives.
View details for DOI 10.1097/MCG.0000000000002066
View details for PubMedID 39312545
-
What's Behind it all: A Retrospective Cohort Study of Retrogastric Pancreatic Necrosis Management.
Annals of surgery
2024
Abstract
To compare outcomes of laparoscopic transgastric necrosectomy (LTN) and direct endoscopic necrosectomy (DEN) in the management of retrogastric walled-off necrosis.Surgical and endoscopic transgastric approaches are used to manage retrogastric pancreatic necrosis. Studies comparing these treatment modalities are lacking but would influence contemporary practice patterns.LTN or DEN treated patients at Stanford University Hospital between 2011 and 2023 were identified. Cohort data included demographics, core pancreatitis care benchmarks, and clinical outcomes (total debridement time, new-onset endocrine and exocrine pancreatic insufficiency) as well as re-intervention, 30-day readmission, complication, and mortality rates. Long-term follow-up was also compared between intervention arms. Multivariable linear regression was used to assess the interaction between admission APACHE-II score and intervention on length of stay (LOS).106 patients (62% LTN, 38% DEN) were identified. Demographic and core pancreatitis benchmark data were similar between cohorts. 30-day readmission, complication, and mortality rates for surgical and endoscopic approaches were also similar: 23% vs. 25% (P = 0.98), 42% vs. 40% (P = 0.97), and 3% vs. 3% (P > 0.99). Median LTN total debridement time (minutes) was 131 vs. 134 for DEN, however, complete debridement was achieved with only 1 LTN compared to 3 DENs (P<0.01). While not statistically significant, LOS and unplanned intervention rates were less for LTN (8 vs. 10 days, P = 0.41 and 6% vs. 15%, P = 0.24). Multivariable analysis revealed a significant interaction between APACHE-II scores and LOS for LTN compared to DEN, which translated into a length of stay reduction for higher APACHE-II scoring patients (P = 0.02).LTN is a safe and efficient treatment modality for walled-off necrosis, and compared to DEN, can reduce the LOS in high APACHE-II score patients. While additional comparative research between the two intervention types is needed, this study supports a role for a surgical approach in the management of retrogastric pancreatic necrosis.
View details for DOI 10.1097/SLA.0000000000006521
View details for PubMedID 39225420
-
Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection and Ablation: A Large North American Multicenter Cohort
AMERICAN JOURNAL OF GASTROENTEROLOGY
2024; 119 (9): 1831-1840
Abstract
Endoscopic eradication therapy (EET) combining endoscopic resection (ER) with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) followed by ablation is the standard of care for the treatment of dysplastic Barrett's esophagus (BE). We have previously shown comparable rates of complete remission of intestinal metaplasia (CRIM) with both approaches. However, data comparing recurrence after CRIM are lacking. We compared rates of recurrence after CRIM with both techniques in a multicenter cohort.Patients undergoing EET achieving CRIM at 3 academic institutions were included. Demographic and clinical data were abstracted. Outcomes included rates and predictors of any BE and dysplastic BE recurrence in the 2 groups. Cox-proportional hazards models and inverse probability treatment weighting (IPTW) analysis were used for analysis.A total of 621 patients (514 EMR and 107 ESD) achieving CRIM were included in the recurrence analysis. The incidence of any BE (15.7, 5.7 per 100 patient-years) and dysplastic BE recurrence (7.3, 5.3 per 100 patient-years) were comparable in the EMR and ESD groups, respectively. On multivariable analyses, the chances of BE recurrence were not influenced by ER technique (hazard ratio 0.87; 95% confidence interval 0.51-1.49; P = 0.62), which was also confirmed by IPTW analysis (ESD vs EMR: hazard ratio 0.98; 95% confidence interval 0.56-1.73; P = 0.94). BE length, lesion size, and history of cigarette smoking were independent predictors of BE recurrence.Patients with BE dysplasia/neoplasia achieving CRIM, initially treated with EMR/ablation, had comparable recurrence rates to ESD/ablation. Randomized trials are needed to confirm these outcomes between the 2 ER techniques.
View details for DOI 10.14309/ajg.0000000000002798
View details for Web of Science ID 001308355500029
View details for PubMedID 38587280
-
Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021.
The lancet. Gastroenterology & hepatology
2024
Abstract
Appendicitis is a common surgical emergency that poses a large clinical and economic burden. Understanding the global burden of appendicitis is crucial for evaluating unmet needs and implementing and scaling up intervention services to reduce adverse health outcomes. This study aims to provide a comprehensive assessment of the global, regional, and national burden of appendicitis, by age and sex, from 1990 to 2021.Vital registration and verbal autopsy data, the Cause of Death Ensemble model (CODEm), and demographic estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) were used to estimate cause-specific mortality rates (CSMRs) for appendicitis. Incidence data were extracted from insurance claims and inpatient discharge sources and analysed with disease modelling meta-regression, version 2.1 (DisMod-MR 2.1). Years of life lost (YLLs) were estimated by combining death counts with standard life expectancy at the age of death. Years lived with disability (YLDs) were estimated by multiplying incidence estimates by an average disease duration of 2 weeks and a disability weight for abdominal pain. YLLs and YLDs were summed to estimate disability-adjusted life-years (DALYs).In 2021, the global age-standardised mortality rate of appendicitis was 0·358 (95% uncertainty interval [UI] 0·311-0·414) per 100 000. Mortality rates ranged from 1·01 (0·895-1·13) per 100 000 in central Latin America to 0·054 (0·0464-0·0617) per 100 000 in high-income Asia Pacific. The global age-standardised incidence rate of appendicitis in 2021 was 214 (174-274) per 100 000, corresponding to 17 million (13·8-21·6) new cases. The incidence rate was the highest in high-income Asia Pacific, at 364 (286-475) per 100 000 and the lowest in western sub-Saharan Africa, at 81·4 (63·9-109) per 100 000. The global age-standardised rates of mortality, incidence, YLLs, YLDs, and DALYs due to appendicitis decreased steadily between 1990 and 2021, with the largest reduction in mortality and YLL rates. The global annualised rate of decline in the DALY rate was greatest in children younger than the age of 10 years. Although mortality rates due to appendicitis decreased in all regions, there were large regional variations in the temporal trend in incidence. Although the global age-standardised incidence rate of appendicitis has steadily decreased between 1990 and 2021, almost half of GBD regions saw an increase of greater than 10% in their age-standardised incidence rates.Slow but promising progress has been observed in reducing the overall burden of appendicitis in all regions. However, there are important geographical variations in appendicitis incidence and mortality, and the relationship between these measures suggests that many people still do not have access to quality health care. As the incidence of appendicitis is rising in many parts of the world, countries should prepare their health-care infrastructure for timely, high-quality diagnosis and treatment. Given the risk that improved diagnosis may counterintuitively drive apparent rising trends in incidence, these efforts should be coupled with improved data collection, which will also be crucial for understanding trends and developing targeted interventions.Bill and Melinda Gates Foundation.
View details for DOI 10.1016/S2468-1253(24)00157-2
View details for PubMedID 39032499
-
Histologic Activity from Neoterminal Ileal Biopsies in Patients with Crohn's Disease in Endoscopic Remission is Associated with Postoperative Recurrence.
The American journal of gastroenterology
2024
Abstract
Following ileocolic resection (ICR), the clinical importance and prognostic implications of histologic activity on biopsies in Crohn's disease (CD) patients with endoscopic remission are not well defined. This study aimed to determine if histologic activity in patients with endoscopic remission is associated with future risk of endoscopic and/or radiologic postoperative recurrence (POR).In this multicenter retrospective cohort study, adult patients with CD who underwent ICR between 2009-2020 with endoscopic biopsies of ileal mucosa from Rutgeerts' i0 on index colonoscopy were included. The composite rate of endoscopic (Rutgeerts' score≥i2b) and radiologic (active inflammation on imaging) recurrence was compared in patients with and without histologic activity using a Kaplan-Meier survival analysis. A multivariable Cox proportional hazard regression model including clinically relevant risk factors for POR, postoperative biologic prophylaxis, and histology activity was designed.A total of 113 patients with i0 disease on index colonoscopy after ICR were included. Of these, 42% had histologic activity. Time to POR was significantly earlier in the histologically active versus normal group (p=0.04). After adjusting for clinical risk factors for POR, histologic activity (HR 2.37, 95% CI 1.17-4.79; p=0.02) and active smoking (HR 2.54, 95% CI 1.02-6.33; p=0.05) were independently associated with subsequent composite POR risk.In patients with postoperative CD, histologic activity despite complete endoscopic remission is associated with composite, endoscopic and radiographic, recurrence. Further understanding of the role of histologic activity in patients with Rutgeerts' i0 disease may provide a novel target to reduce disease recurrence in this population.
View details for DOI 10.14309/ajg.0000000000002963
View details for PubMedID 39007494
-
Postoperative Crohn's Disease Recurrence Risk and Optimal Biologic Timing After Temporary Diversion Following Ileocolic Resection
INFLAMMATORY BOWEL DISEASES
2024; 31 (3): 686-695
Abstract
Postoperative recurrence of Crohn's disease (CD) is common. While most patients undergo resection with undiverted anastomosis (UA), some individuals also have creation of an intended temporary diversion (ITD) with an ileostomy followed by ostomy takedown (OT) due to increased risk of anastomotic complications. We assessed the association of diversion with subsequent CD recurrence risk and the influence of biologic prophylaxis timing to prevent recurrence in this population.This was a retrospective cohort study of CD patients who underwent ileocolic resection between 2009 and 2020 at a large quaternary health system. Patients were grouped by continuity status after index resection (primary anastomosis or ITD). The outcomes of the study were radiographic, endoscopic, and surgical recurrence as well as composite recurrence postoperatively (after OT in the ITD group). Propensity score-weighted matching was performed based on risk factors for diversion and recurrence. Multivariable regression and a Cox proportional hazards model adjusting for recurrence risk factors were used to assess association with outcomes. Subgroup analysis in the ITD group was performed to assess the impact of biologic timing relative to OT (no biologic, biologic before OT, after OT) on composite recurrence.A total of 793 CD patients were included (mean age 38 years, body mass index 23.7 kg/m2, 52% female, 23% active smoker, 50% penetrating disease). Primary anastomosis was performed in 67.5% (n = 535) and ITD in 32.5% (n = 258; 79% loop, 21% end) of patients. Diverted patients were more likely to have been males and to have had penetrating and perianal disease, prior biologic use, lower body mass index, and lower preoperative hemoglobin and albumin (all P < .01). After a median follow-up of 44 months, postoperative recurrence was identified in 83.3% patients (radiographic 40.4%, endoscopic 39.5%, surgical 13.3%). After propensity score matching and adjusting for recurrence risk factors, no significant differences were seen between continuity groups in radiographic (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 0.91-1.91) or endoscopic recurrence (aHR, 1.196; 95% CI, 0.84-1.73), but an increased risk of surgical recurrence was noted in the ITD group (aHR, 1.61; 95% CI, 1.02-2.54). Most (56.1%) ITD patients started biologic prophylaxis after OT, 11.4% before OT, and 32.4% had no postoperative biologic prophylaxis. Biologic prophylaxis in ITD was associated with younger age (P < .001), perianal disease (P = .04), and prior biologic use (P < .001) but not in recurrence (P = .12). Despite higher rates of objective disease activity identified before OT, biologic exposure before OT was not associated with a significant reduction in composite post-OT recurrence compared with starting a biologic after OT (52% vs 70.7%; P = 0.09).Diversion of an ileocolic resection is not consistently associated with a risk of postoperative recurrence and should be performed when clinically appropriate. Patients requiring diversion at time of ileocolic resection are at high risk for recurrence, and biologic initiation prior to stoma reversal may be considered.
View details for DOI 10.1093/ibd/izae117
View details for Web of Science ID 001240105700001
View details for PubMedID 38842693
-
OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL SQUAMOUS NEOPLASMS: A MULTICENTER NORTH AMERICAN EXPERIENCE
MOSBY-ELSEVIER. 2024: AB1068-AB1069
View details for Web of Science ID 001278323004174
-
LONG TERM OUTCOMES OF NON-CURATIVE ENDOSCOPIC SUBMUCOSAL DISSECTION FOR COLORECTAL LESIONS
MOSBY-ELSEVIER. 2024: AB469-AB470
View details for Web of Science ID 001278323001422
-
OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL SQUAMOUS NEOPLASMS: A MULTICENTER NORTH AMERICAN EXPERIENCE
MOSBY-ELSEVIER. 2024: AB992-AB993
View details for Web of Science ID 001278323004037
-
Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021
LANCET NEUROLOGY
2024; 23 (4): 344-381
Abstract
Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.We estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.Globally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378-521), affecting 3·40 billion (3·20-3·62) individuals (43·1%, 40·5-45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7-26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6-38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5-32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7-2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed.Bill & Melinda Gates Foundation.
View details for DOI 10.1016/S1474-4422(24)00038-3
View details for Web of Science ID 001270049900001
View details for PubMedID 38493795
View details for PubMedCentralID PMC10949203
-
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
ECLINICALMEDICINE
2023; 64: 102193
Abstract
The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019.We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends.In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of -0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = -0.41), inflammatory bowel disease (AAPC = -0.72), multiple sclerosis (AAPC = -0.26), psoriasis (AAPC = -0.77), and atopic dermatitis (AAPC = -0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR.The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively.The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38).
View details for DOI 10.1016/j.eclinm.2023.102193
View details for Web of Science ID 001084747100001
View details for PubMedID 37731935
View details for PubMedCentralID PMC10507198
-
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
LANCET
2023; 402 (10397): 203-234
Abstract
Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050.Estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively.In 2021, there were 529 million (95% uncertainty interval [UI] 500-564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8-6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7-9·9]) and, at the regional level, in Oceania (12·3% [11·5-13·0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76·1% (73·1-79·5) in individuals aged 75-79 years. Total diabetes prevalence-especially among older adults-primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1-96·8) of diabetes cases and 95·4% (94·9-95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5-71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5-30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22-1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1-17·6) in north Africa and the Middle East and 11·3% (10·8-11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%.Diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers.Bill & Melinda Gates Foundation.
View details for DOI 10.1016/S0140-6736(23)01301-6
View details for Web of Science ID 001084390700001
View details for PubMedID 37356446
View details for PubMedCentralID PMC10364581
-
ENDOSCOPIC SUBMUCOSAL DISSECTION OF ESOPHAGEAL ADENOCARCINOMA DEEMED PATHOLOGICALLY CURATIVE RESULTS IN FEW RECURRENCES AT LONG-TERM SURVEILLANCE: A NORTH AMERICAN STUDY
MOSBY-ELSEVIER. 2023: AB1105-AB1106
View details for Web of Science ID 001038022802459
-
ENDOSCOPIC SUBMUCOSAL DISSECTION OF ESOPHAGEAL ADENOCARCINOMA DEEMED PATHOLOGICALLY CURATIVE RESULTS IN FEW RECURRENCES AT LONG-TERM SURVEILLANCE: A NORTH AMERICAN STUDY
MOSBY-ELSEVIER. 2023: AB1018-AB1019
View details for Web of Science ID 001038022802336
-
OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR PREVIOUSLY ATTEMPTED COLORECTAL LESIONS: AN INTERNATIONAL MULTICENTER EXPERIENCE
MOSBY-ELSEVIER. 2023: AB430-AB431
View details for Web of Science ID 001038022801059
-
Initial Multicenter Experience of Traction Wire Endoscopic Submucosal Dissection
TECHNIQUES AND INNOVATIONS IN GASTROINTESTINAL ENDOSCOPY
2023; 25 (1): 21-29
View details for DOI 10.1016/j.tige.2022.10.002
View details for Web of Science ID 001035713900001
https://orcid.org/0000-0002-5446-6127